Regeneron’s gene therapy Otarmeni (lunsotogene parvec) won U.S. FDA approval for a rare inherited form of hearing loss caused by variants in the otoferlin gene. The approval marks the first clearance under the agency’s National Priority Voucher program and positions Otarmeni as a potential milestone for the accelerated gene-therapy pathway. According to Regeneron and coverage of the approval, the company plans to offer the treatment at no cost to eligible patients in the U.S. Early study results described at the time of clearance reported modest hearing gains in participants with ultra-rare disease. The FDA’s action also comes alongside a policy backdrop: Regeneron previously linked the voucher program to the value of an additional pediatric priority voucher, highlighting how new regulatory tools can change gene-therapy commercial economics. Bottom line for biotech developers and investors: Otarmeni’s approval adds another datapoint for how the National Priority Voucher program is being used to shorten time to market for gene therapies targeting rare pediatric conditions.